Fig. 5From: EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanismsCorrelations between EXTL3 expression and A immune cells infiltration; B tumor microenvironment; C immune checkpoint molecules; D immune cells; *P < 0.05; **P < 0.01;***P < 0.001Back to article page